Session Name News Today

Poolbeg Pharma PLC Announces POLB 001 Data to be Presented at American ...

VIP943 poster supports selectivity and safety of lead CD123 ADC, VIP943, currently in Phase 1 VIP924 poster shows this novel CXCR5-ADC compares favorably with other ADCs in clinical development Enitociclib poster expands potential clinical indications PALO ALTO, Calif., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutic...

Protagonist Therapeutics Announces Abstracts Selected for Oral and ...

/PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage oncology company, developing new precision medicine treatment options for cancer...

Chickasaw Journal E-Edition Delivery Are you a Chickasaw Journal subscriber? Sign up to view our weekly e-editions each Wednesday with just a click.  Itawamba Times E-Edition Delivery Are you an Itawamba Times subscriber? Sign up to view our weekly e-editions each Wednesday with just a click. Monroe Journal E-Edition Delivery Are you a Monroe Journal subscriber? Sign up to view our weekly e-editions each Wednesday with just a click. New Albany Gazette E-Edition Delivery Are you a New Alban...

Sierra Oncology Announces Abstracts Accepted for American Society of Clinical Oncology Annual Meeting News provided by Share this article independence and overall survival to be presented— SAN MATEO, Calif., May 19, 2021  May 19, 2021 - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced three abstracts have been accepted into the program for the 2021 Annual Meeting of the American So...